Khurem Farooq, Aiolos Bio CEO
October 24, 2023 07:00 AM EDTUpdated 09:31 AM
Financing
Startups

Aio­los Bio launch­es with $245M Se­ries A, chas­ing one of asth­ma’s hottest tar­gets

Andrew Dunn

Senior Biopharma Correspondent

Two Genen­tech vets have land­ed one of biotech’s largest Se­ries A rounds of 2023 as they launch Aio­los Bio to ad­vance an asth­ma drug in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times